Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 3/20 | 0.55 |
| ▸ | GSR | P00390 | 1/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 2/20 | 0.45 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.45 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextroamphetamine SCHEMBL19873157 | 1.00 | THRB (0.59) | THRBMMP2GSRALPIPKM | |
| Amphetamine SCHEMBL969812 | 1.00 | THRB (0.59) | THRBMMP2GSRALPIPKM | |
| Amphetamine SCHEMBL27878191 | 1.00 | THRB (0.59) | THRBMMP2GSRALPIPKM | |
| Amphetamine SCHEMBL578976 | 0.93 | GSR (0.59) | THRBMMP2GSRALPIPKM | |
| Amphetamine SCHEMBL27917387 | 0.93 | GSR (0.59) | THRBMMP2GSRALPIPKM | |
| Amphetamine SCHEMBL578608 | 0.93 | GSR (0.59) | THRBMMP2GSRALPIPKM | |
| Amphetamine SCHEMBL28843066 | 0.93 | GSR (0.59) | THRBMMP2GSRALPIPKM | |
| Amphetamine SCHEMBL969267 | 0.92 | GSR (0.57) | THRBMMP2GSRALPIPKM | |
| Lysine SCHEMBL20836835 | 0.90 | MMP2 (0.50) | THRBMMP2GSRALPIPKM | |
| Amphetamine SCHEMBL4563535 | 0.89 | SLC6A2 (0.58) | THRBMMP2GSRALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116270513-A | A compound oral pharmaceutical dosage form containing fixed dose of ADHD non-agonist and ADHD agonist | 南京三迭纪医药科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-108348517-B | Non-selective metabotropic glutamate receptor activators for the treatment of attention deficit disorder and 22Q syndrome | 费城儿童医院 | 2021-11-05 | — | — | CN | disclosed |
| CN-105744983-B | Device and method for sustained release of therapeutic agents of low water solubility in solubilizing agents | 纳米医学系统公司 | 2019-12-27 | — | — | CN | disclosed |
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-7723305-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7718619-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-18 | — | — | US | disclosed |
| US-7713936-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-7700561-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090131334-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131335-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131332-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090124831-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124700-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124696-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1865980-A2 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | New River Pharmaceuticals Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006121552-A9 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | NEW RIVER PHARMACEUTICALS INC (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070042955-A1 | Abuse-resistant amphetamine prodrugs | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2006121552-A2 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131332-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885THRB 2724/4885 |
| US-20070042955-A1 | Abuse-resistant amphetamine prodrugs | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885THRB 2724/4885 |
| US-20090124700-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885THRB 2724/4885 |
| US-20090124696-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885THRB 2724/4885 |
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885THRB 2724/4885 |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885THRB 2724/4885 |
| US-20090124831-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885THRB 2724/4885 |
| US-20090131334-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885THRB 2724/4885 |
| US-20090131335-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885THRB 2724/4885 |
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885THRB 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.